580 - Pharmacokinetics (PK) and Safety of Nirmatrelvir/Ritonavir (NMV/r) in Non-Hospitalized Symptomatic Pediatric Patients Ages 6 Years and Older with COVID-19 who are at Increased Risk of Progression to Severe Disease (EPIC-Peds)

Presenting Author(s)

• 

  Jacqueline Gerhart, PhD, MBA, MS

  Clinical Pharmacology Lead
  Pfizer
  Collegeville, PA, United States

  Slides

Co-Author(s)

• HL

  Heidi Leister-Tebbe, BSN (she/her/hers)

  Clinician/Clinical Lead
  Pfizer Inc
  Collegeville, Pennsylvania, United States
• NS

  Namita Singh, MD

  Pfizer
  New York City, New York, United States
• PC

  Phylinda L. S. Chan, PhD

  Director
  Pfizer
  Sandwich, Kent, England, United Kingdom
• HS

  Haihong Shi, MS, MBA

  Pfizer
  Groton, Connecticut, United States
• WC

  William D H Carey, MBBS, PhD, MRCPI

  Director
  Pfizer
  Walton Oaks, England, United Kingdom
• JY

  Jean Yan, M.S.

  Pfizer Inc., Sanford, Florida, USA
  Sanford, Florida, United States
• 

  Mary Lynn Baniecki, PhD

  Head of Infectious Disease for Translational Medicine
  Pfizer Inc
  Cambridge, Massachusetts, United States
• VH

  Victoria Hendrick, BSc

  Pfizer
  Sandwich, England, United Kingdom
• WW

  Wayne Wisemandle, MA

  Pfizer Inc
  Wake Forest, Illinois, United States
• RS

  Ravi Shankar P. Singh, PhD, FCP

  Pfizer
  Cambridge, Massachusetts, United States
• 

  Jennifer Hammond, PhD

  Head of Antiviral Development
  Pfizer Inc
  Collegeville, PA, United States